Tubulis
About Tubulis
Tubulis is a biotechnology company focused on developing antibody-drug conjugates for oncology. They design and advance ADC candidates for solid and hematologic tumors, with lead programs TUB-040 targeting NaPi2b and TUB-030 targeting 5T4, currently in clinical evaluation. The company emphasizes proprietary technology to improve biophysical properties, tumor delivery, and durability of anti-tumor activity, and operates primarily in Europe. Headquartered in Germany, Tubulis aims to expand the therapeutic potential of ADCs for patients and collaborations with partners.
Recent News
Gilead Sciences Completes Tubulis Acquisition for $5bn
STAT+: Gilead to Buy Cancer Biotech Tubulis for More than $3 Billion
Kymera Therapeutics Reports Gilead’s Option Exercise to License KT-200, a CDK2 Molecular Glue Degrader
Gilead Reports the US FDA Accelerated Approval of Hepcludex to Treat Chronic Hepatitis Delta Virus (HDV) Infection
Gilead to Acquire Germany's Tubulis for Up to $5 B, Boosting ADC Portfolio
HTGF: Where Public Mandate Meets Venture Discipline
Top Biotech Deals in April 2026
Gilead and Roche Bet on Protein Degraders for Their Cancer Drug Pipelines
Drugs From a Text Prompt, Wegovy Pill Competition Dampens Lilly’s Surge
2021 Sparked a Banner Year for Biotech IPOs. Where Are They Now?
TSMC Posts 35% Jump in Q1 Revenue
CellCentric Secures $220M in Europe’s Biggest Private Biotech Fundraise of 2026
Recent Deals
Gilead Sciences to Acquire Tubulis, Adding ADC Platform to Oncology Pipeline
Gilead Sciences Completes Tubulis Acquisition for up to $5bn
Gilead to Acquire Tubulis for ~$5B
Tubulis Raises €308M (USD 361M) in Series C Led by Venrock Healthcare Capital Partners